Literature DB >> 1933884

Differential binding and biological activities of epidermal growth factor and transforming growth factor alpha in a human pancreatic cancer cell line.

M Korc1, B Chandrasekar, G N Shah.   

Abstract

The binding characteristics and biological activities of epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha) were studied in T3M4 human pancreatic cancer cells. Scatchard analysis of 125I-EGF binding data at pH 7.4 indicated the presence of two orders of binding sites: a high-affinity site (Kd = 0.58 nM; 25,300 sites/cell) and a low-affinity site (Kd = 7.0 nM; 484,000 sites/cell). At pH 8.5, there was a decrease in the number of high-affinity sites. In contrast, only a single order of high-affinity sites was detected with 125I-TGF-alpha at either pH 7.4 (Kd = 0.57 nM; 100,200 sites/cell) or pH 8.5 (Kd = 0.70 nM; 230,400 sites/cell). The two ligands bound to the same receptor, as determined in cross-linking experiments and in competitive binding assays performed in the presence of an anti-EGF receptor antibody that allows for EGF binding. Phosphoamino acid analysis of the immunoprecipitated EGF receptor indicated that EGF exerted a greater effect than TGF-alpha on tyrosine phosphorylation of the receptor. EGF and TGF-alpha also exhibited different potencies with respect to their effects on inositol 1,4,5-trisphosphate generation and exerted divergent effects on the kinetics of inositol 1,4,5-trisphosphate formation. These findings point to dissimilar interactions of EGF and TGF-alpha with the EGF receptor in T3M4 cells, which may lead to differential activation of signal transduction pathways by these ligands.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933884

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

2.  Overexpression of caspase-1 in pancreatic disorders: implications for a function besides apoptosis.

Authors:  M Ramadani; F Gansauge; S Schlosser; Y Yang; H G Beger; S Gansauge
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

3.  Transforming growth factor alpha (TGF-alpha) increases cell number in a human pancreatic cancer cell line but not in normal mouse pancreas.

Authors:  B Kullenberg; C Jansen; N Fredäng; B Ohlsson; J Axelson
Journal:  Int J Pancreatol       Date:  2000-12

4.  Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells.

Authors:  T Oikawa; J Hitomi; A Kono; E Kaneko; K Yamaguchi
Journal:  Int J Pancreatol       Date:  1995-08

5.  Overexpression of Caspase-1 in adenocarcinoma of pancreas and chronic pancreatitis.

Authors:  Yin-Mo Yang; Marco Ramadani; Yan-Ting Huang
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

6.  Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.

Authors:  M Korc; B Chandrasekar; Y Yamanaka; H Friess; M Buchier; H G Beger
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

7.  A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.

Authors:  T Moriai; M S Kobrin; C Hope; L Speck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver.

Authors:  E P Sandgren; N C Luetteke; T H Qiu; R D Palmiter; R L Brinster; D C Lee
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

9.  Constitutive over-expression of transforming growth factor-alpha in rat liver epithelial cells leads to increased cell cycling without transformation.

Authors:  T B Tan; P A Marino; R Padmanabhan; L L Hampton; J M Hanley-Hyde; S S Thorgeirsson
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-09       Impact factor: 2.416

10.  The inhibitory effect of an EGF receptor-specific tyrosine kinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF I.

Authors:  M Kobari; B Kullenberg; A Björkman; S Matsuno; I Ihse; J Axelson
Journal:  Int J Pancreatol       Date:  1998-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.